Cellectar Biosciences completes 1-for-30 reverse stock split effective June 24, 2025

Cellectar Biosciences, Inc.

Reverse split ratio set at 1-for-30 for common stock, par value $0.00001.
Amendment to Second Amended and Restated Certificate of Incorporation filed.
Fractional shares not issued; aggregate fractions sold by transfer agent and net proceeds distributed pro rata.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cellectar Biosciences, Inc.: Effected a one-for-thirty reverse stock split by amending the Second Amended and Restated Certificate of Incorporation (effective 2025-06-24).

Change: charter amendment
Effective: 2025-06-24

Exact text from the filing

On June 24, 2025, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), effected a one-for-thirty reverse stock split of the Company’s common stock, par value $0.00001 (the “Reverse Split”) by amending its Second Amended and Restated Certificate of Incorporation (the “Amendment”).

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-062639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.